Evaluation of the sST2-guided optimization of medical treatments of patients admitted for heart failure, to prevent readmission: Study protocol for a randomized controlled trial

Curinier, Corentin; Solecki, Kamila; Dupuy, Anne‐Marie; Breuker, Cyril; Lotierzo, Manuela; Zerkowski, L.; Kalmanovich, Eran; Akodad, Mariama; Adda, Jérôme; Battistella, Pascal; Castet‐Nicolas, Audrey; Kuster, Nils; Marques, Sandra Márcia Tietz; Soltani, Sonia; Chettouh, Marine; Verchere, Anne; Belloc, Claire; Roubille, Camille; Fesler, Pierre; Mercier, Grégoire; Cristol, Jean‐Paul; Audurier, Yohan; Roubille, François

doi:10.1016/j.cct.2018.01.007

Cited by 8 publications

(3 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the intervention group (ST2 group), the treatment was optimized following the value of the sST2; in the control group (BNP group), the cardiologists was blinded to the sST2 and optimized the treatment following usual practice. The design paper was published elsewhere [ 13 ] and referenced in clinical trial (NCT02963272).…”

Section: Methodsmentioning

confidence: 99%

Soluble urokinase-type Plasminogen Activator Receptor Strongly Predicts Global Mortality in Acute Heart Failure Patients: Insight From the STADE-HF Registry

et al. 2021

Self Cite

View full text Add to dashboard Cite

Background: Whether soluble urokinase-type plasminogen activator receptor (suPAR) could be a valuable prognostic indicator remains uncertain. Materials & methods: Patients from STADE-HF (Soluble Suppression of Tumorigenesis-2 as a Help for Management of Diagnosis, Evaluation and Management of Heart Failure) were included for analysis. Results: 95 patients were included. The suPAR level of expression was significantly higher in the group of patients who died at one month (7.90 ± 4.35 ng/ml vs 11.94 ± 6.86 ng/ml; p < 0.05) or 1 year (7.28 ± 4.27 ng/ml vs 11.81 ± 4.88 ng/ml; p < 0.01), but there was no significant difference according to the readmission. Conclusion: High suPAR levels during hospitalization for acute heart failure were highly predictive for the risk of mortality, but not the risk of readmission.

show abstract

Section: Methodsmentioning

confidence: 99%

Soluble urokinase-type Plasminogen Activator Receptor Strongly Predicts Global Mortality in Acute Heart Failure Patients: Insight From the STADE-HF Registry

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…К настоящему времени нет ни одного завершившегося исследования эффективности sST2-управляемой терапии. Однако такие работы начаты во Франции (исследование STADE-HF) [82] и в России в ФГБУ «НМИЦ кардиологии» МЗ РФ.…”

Section: терапия сн под контролем Sst2новые перспективы?unclassified

Натрийуретические Пептиды И Растворимый ST2-рецептор: Роль В Диагностике, Стратификации Риска И Лечении Больных С Хронической Сердечной Недостаточностью

Muksinova¹,

Narusov²,

Скворцов³

2019

Kardiologicheskii Vestnik

View full text Add to dashboard Cite

Обзорная статья посвящена значению определения концентраций натрийуретических пептидов (НУП) и нового биомаркера sST2 для диагностики, оценки прогноза и лечения пациентов с сердечной недостаточностью. В статье обсуждаются слабые и сильные стороны этих биомаркеров и их место в современных рекомендациях. Подробно изложены результаты исследований, в которых продемонстрирована высокая прогностическая ценность sST2 у пациентов c острой декомпенсацией сердечной недостаточности и стабильной хронической сердечной недостаточностью (ХСН). Обоснованы возможность использования sST2 для стратификации риска и оценки эффективности лечения у больных с ХСН и его преимущество по сравнению с НУП. Обсуждены основные исследования, посвященные проблеме лечения больных с ХСН под контролем концентрации НУП, и детально проанализированы причины неудач работ, в которых не удалось показать превосходство НУП-управляемой терапии над стандартным подходом к лечению. Приведены теоретические предпосылки эффективности использования для этой цели sST2.

show abstract

“…However, when the cardiac load increases, the secretion of sST2 increases, and the sST2 reduces the cardiac protective effect of the IL-33/ST2L signal pathway by competitive binding to IL-33. 13,14 It was inferred that sST2 may be the pathogenetic mediator leading to myocardial hypertrophy and myocardial brosis. sST2 is directly related to the myocardial brosis response aer injury and can reect the degree of myocardial brosis and ventricular remodeling in patients with HF.…”

Section: Introductionmentioning

confidence: 99%

A rapid and quantitative detection method for plasma soluble growth stimulating gene protein 2 based on time resolved fluorescence immunochromatography

et al. 2022

View full text Add to dashboard Cite

show abstract

Evaluation of the sST2-guided optimization of medical treatments of patients admitted for heart failure, to prevent readmission: Study protocol for a randomized controlled trial

Abstract: HAL is a multidisciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

Cited by 8 publications

References 39 publications

Soluble urokinase-type Plasminogen Activator Receptor Strongly Predicts Global Mortality in Acute Heart Failure Patients: Insight From the STADE-HF Registry

Soluble urokinase-type Plasminogen Activator Receptor Strongly Predicts Global Mortality in Acute Heart Failure Patients: Insight From the STADE-HF Registry

Натрийуретические Пептиды И Растворимый ST2-рецептор: Роль В Диагностике, Стратификации Риска И Лечении Больных С Хронической Сердечной Недостаточностью

A rapid and quantitative detection method for plasma soluble growth stimulating gene protein 2 based on time resolved fluorescence immunochromatography

Contact Info

Product

Resources

About